The prevalence of <i>EGFR</i> mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

Zhang, Yuelun; Yuan, Jinqiu; Wang, Kaifeng; Fu, Xiaohong; Han, Xiao-Ran; Threapleton, Diane; Yang, Zu‐Yao; Chen, Mao; Tang, Jin‐Ling

doi:10.18632/oncotarget.12587

Cited by 601 publications

(472 citation statements)

References 41 publications

Supporting

Mentioning

416

Contrasting

Unclassified

Order By: Relevance

“…Examining its mutation is not only important to understand tumorigenicity element in NSCLC but also crucial to patient treatment with TKI-targeting therapy. Even mostly consistent with previous reports, 3,19 our data still provides some important information in this dominated abnormality of LAC. Our results showed that L858R in exon 21 (51/93, 54.83%) and exon 19 deletions (38/93, 40.86%) are the two major defects which account for more than 95% EGFR mutations in LAC.…”

Section: Discussionsupporting

confidence: 93%

High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients

Zhang

et al. 2017

Tumour Biol.

View full text Add to dashboard Cite

Dysregulation of SLC34A2 (NaPi2b) in tumors has attracted wide attention, but its expression and function in nonsmall cell lung cancer remains unclear. By examining its expression in lung adenocarcinoma and correlation to patient outcome, we aimed to explore its prognostic and therapeutic values in this deadly disease. Overall, 175 cases of lung adenocarcinoma sample were included in this study. Histological subtyping of them was diagnosed according to standards of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society in 2011. Protein expression of SLC34A2 and anaplastic lymphoma kinase in these samples was determined by immunohistochemistry. Epidermal growth factor receptor mutations were examined using amplification refractory mutation system. Statistical analysis was performed using software of Pearson's correlation coefficient. High expression of SLC34A2 was identified in about 2/3 patients and correlated with significantly better patient's overall survival. Epidermal growth factor receptor mutations were detected in about 53% of patients with no statistically significant difference to patient's overall survival. Anaplastic lymphoma kinase rearrangement was found in 8 out of 175 patients, harboring this abnormality leads to shorter overall survival. No correlation has been found between SLC34A2 expression and epidermal growth factor receptor mutation or anaplastic lymphoma kinase rearrangements in lung adenocarcinoma. High expression of SLC34A2 is present in about 3/4 lung adenocarcinoma samples and predicts better outcome. Since it is a membrane protein, antibody-based drugs targeting this marker might bring new resolution to this deadly disease.

show abstract

Section: Discussionsupporting

confidence: 93%

High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients

Zhang

et al. 2017

Tumour Biol.

View full text Add to dashboard Cite

show abstract

“…Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers and the cornerstone of management for advanced stage disease has traditionally been cytotoxic chemotherapy, albeit with low response rates (20% to 25%) and overall survival (OS) of 10-12 months (2,3). The discovery of driver mutations in the epidermal growth factor receptor (EGFR) gene in a subset of patients with NSCLC and the development of oral tyrosine kinase inhibitors (TKIs) targeting these mutant receptors has remarkably changed the therapeutic landscape in advanced NSCLC.…”

Section: Introductionmentioning

confidence: 99%

“…It has led to improved progression free survival as well as quality of life in this patient population (4). The prevalence of sensitizing EGFR mutation ranges from 14% to 38% in patients with NSCLC depending on geographic location and ethnicity (3). These mutations are more commonly present in women, nonsmokers and Asian populations.…”

Section: Introductionmentioning

confidence: 99%

Circulating DNA in EGFR-mutated lung cancer

Singh¹,

Li²,

Cheng³

2017

Ann. Transl. Med.

View full text Add to dashboard Cite

Circulating tumor DNA (ctDNA) consists of short double stranded DNA fragments that are released by tumors including non-small cell lung cancer (NSCLC). With the identification of driver mutations in the epidermal growth factor receptor (EGFR) gene and development of targeted tyrosine kinase inhibitors (TKIs), the clinical outcome of NSCLC patients in this subgroup has improved tremendously.The gold standard to assess EGFR mutation is through tissue biopsy, which can be limited by difficulty in accessing the tumor, inability of patients to tolerate invasive procedures, insufficient sample for molecular testing and inability to capture intratumoral heterogeneity. The great need for rapid and accurate identification of activating EGFR mutations in NSCLC patients paves the road for ctDNA technology.Studies have demonstrated ctDNA to be a reliable complement to tumor genotyping. Platforms like digital polymerase chain reaction (PCR) and next-generation sequencing based analyses have made it possible to identify EGFR mutations in plasma with high sensitivity and specificity. This article will provide an overview on ctDNA in the context of EGFR mutated NSCLC, especially its emerging applications in diagnosis, disease surveillance, treatment monitoring and detection of resistance mechanisms.

show abstract

“…While the EGFR is commonly upregulated in many cancers such as in non‐small‐cell lung cancer (NSCLC), metastatic colorectal cancer, glioblastoma, head and neck cancer, pancreatic cancer and breast cancer, erlotinib is currently approved to be used in metastatic non‐small‐cell lung cancer and metastatic pancreatic cancer . In fact, since the oncogenic activation of the EGFR gene is implicated as a driver mechanism in 14.1%‐38.4% of NSCLC tumours, EGFR TKIs have become the standard‐of‐care in the treatment of stage IV NSCLC …”

Section: What Is Known and Objectivementioning

confidence: 99%

Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non‐small‐cell lung cancer

et al. 2019

View full text Add to dashboard Cite

What is known and objective Erlotinib is a small molecule tyrosine kinase inhibitor which blocks the activation of epidermal growth factor receptor (EGFR), a transmembrane receptor that is upregulated in many cancer types. Inhibition of angiogenesis with consequent impairments in intratumoral microcirculation is one of the mechanisms through which EGFR inhibition halts the progression of cancer. A consequence of impaired microcirculation is intratumoral hypoxia, which results in increases in serum uric acid levels. The goal of this study was to investigate the relationship between serum uric acid levels and response to erlotinib in metastatic non‐small‐cell lung cancer (NSCLC). Methods A total of 56 patients with metastatic non‐small‐cell lung cancer who received erlotinib for a duration of at least 3 months were included in this retrospective cohort study. Demographic characteristics, progression status, baseline serum uric levels and 3‐month serum uric acid levels were recorded and analysed. Results and discussion Of the study population, 21 (37.5%) were female and 35 (62.5%) were male patients. No significant difference in above demographic characteristics was observed among exitus, survivor with progression and survivor without progression groups. Patients who responded favourably to erlotinib with no progression of their disease had significantly increased uric acid levels at 3‐month follow‐up (P = .01). Such a correlation was not observed if the patient was exitus (P = .47) or had progressed on erlotinib therapy (P = .19). What is new and conclusion In conclusion, this study is the first to demonstrate significant increases in serum uric acid levels in patients with metastatic NSCLC who responded favourably to erlotinib and had no progression under erlotinib therapy. Further studies are required to confirm and characterize serum uric acid as a novel biomarker in predicting the outcome in those with metastatic NSCLC.

show abstract

The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

Cited by 601 publications

References 41 publications

High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients

High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients

Circulating DNA in EGFR-mutated lung cancer

Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non‐small‐cell lung cancer

Contact Info

Product

Resources

About